A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease

Trial Profile

A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2014

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms FER-IBD-MAIN
  • Sponsors Vifor
  • Most Recent Events

    • 26 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top